Discriminating between 5-HT3A and 5-HT3AB receptors

British Journal of Pharmacology

Volumn 169, Issue 4, 2013, Pages 736-747

  Thompson, A J ^a   Lummis, S C R ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

5 HT3A; 5 HT3AB; 5 HT3B; 5 HT3; allosteric; antagonist; Cys loop; ion channel; ligand; ligand gated

Indexed keywords

5 HYDROXYINDOLE; ABSINTHOL; ANESTHETIC AGENT; ANTINEOPLASTIC AGENT; BILOBALIDE; CHLOROQUINE; DILTIAZEM; ETOMIDATE; GINKGOLIDE B; GRANISETRON; IRINOTECAN; MEFLOQUINE; METHADONE; MORPHINE; PENTOBARBITAL; PICROTOXIN; PICROTOXININ; PROPOFOL; QUININE; SEROTONIN 3 ANTAGONIST; SEROTONIN 3A RECEPTOR; SEROTONIN 3AB RECEPTOR; SEROTONIN 3B RECEPTOR; TOPOTECAN; TUBOCURARINE CHLORIDE; UNCLASSIFIED DRUG;

ALLOSTERISM; BINDING AFFINITY; BINDING SITE; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COMPETITIVE INHIBITION; CRYSTAL STRUCTURE; HUMAN; IC 50; IRRITABLE COLON; LIGAND BINDING; NAUSEA AND VOMITING; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RECEPTOR BLOCKING; RECEPTOR DOWN REGULATION; REVIEW; UNSPECIFIED SIDE EFFECT;

ALLOSTERIC REGULATION; ANIMALS; ANTIEMETICS; BINDING SITES; BINDING, COMPETITIVE; DRUG PARTIAL AGONISM; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PROTEIN MULTIMERIZATION; PROTEIN SUBUNITS; RECEPTORS, SEROTONIN, 5-HT3; RECOMBINANT PROTEINS; SEROTONIN 5-HT3 RECEPTOR AGONISTS; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS;

EID: 84878288719     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12166     Document Type: Review

References (84)

1. A receptor channel. J Gen Physiol 129: 145-159.
2. 3 receptors by morphine. Br J Pharmacol 165: 693-704.
3. 3 receptor-the relationship between structure and function. Neuropharmacology 56: 273-284.
4. 3 receptors. Proc Natl Acad Sci U S A 102: 12595-12600.
5. Boess FG, Beroukhim R, Martin IL, (1995). Ultrastructure of the 5-hydroxytryptamine3 receptor. J Neurochem 64: 1401-1405.
6. Boorman JP, Groot-Kormelink PJ, Sivilotti LG, (2000). Stoichiometry of human recombinant neuronal nicotinic receptors containing the β3 subunit expressed in Xenopus oocytes. J Physiol 529: 565-577.
7. Brady CA, Stanford IM, Ali I, Lin L, Williams JM, Dubin AE, et al. (2001). Pharmacological comparison of human homomeric 5-HT3A receptors versus heteromeric 5-HT3A/3B receptors. Neuropharmacology 41: 282-284.
8. 3 receptor ligands. 1. Further structure-activity relationships and pharmacological characterization. J Med Chem 52: 6946-6950.
9. 3 receptor with quipazine-like arylpiperazine ligands. The journey track at the end of the first decade of the third millennium. Curr Top Med Chem 10: 504-526.
10. 3 receptor. ACS Med Chem Lett 2: 571-576.
11. A receptor. J Neurosci 16: 5415-5424.
12. Colquhoun D, (1998). Binding, gating, affinity and efficacy: the interpretation of structure- activity relationships for agonists and of the effects of mutating receptors. Br J Pharmacol 125: 924-947.
13. 3A receptor. Brain Res Mol Brain Res 119: 207-212.
14. Das P, Dillon GH, (2005). Molecular determinants of picrotoxin inhibition of 5-hydroxytryptamine type 3 receptors. J Pharmacol Exp Ther 314: 320-328.
15. A receptor antagonist picrotoxin inhibits 5-hydroxytryptamine type 3A receptors. Neuropharmacology 44: 431-438.
16. 3 receptor. Curr Opin Pharmacol 11: 75-80.
17. Davies PA, Pistis M, Hanna MC, Peters JA, Lambert JJ, Hales TG, et al. (1999). The 5-HT3B subunit is a major determinant of serotonin-receptor function. Nature 397: 359-363.
18. 3 receptor subunit heterogeneity from a computational point of view. Phys Chem Chem Phys 14: 12625-12636.
19. Deeb TZ, Sharp D, Hales TG, (2009). Direct subunit-dependent multimodal 5-hydroxytryptamine3 receptor antagonism by methadone. Mol Pharmacol 75: 908-917.
20. 3 receptor activity by an effect on the agonist-reduced desensitization. Neuropharmacology 46: 192-201.
21. 3 receptors. Br J Pharmacol 114: 1641-1651.
22. 3B receptor subunit. J Biol Chem 274: 30799-30810.
23. Durisic N, Godin AG, Wever CM, Heyes CD, Lakadamyali M, Dent JA, (2012). Stoichiometry of the human glycine receptor revealed by direct subunit counting. J Neurosci 32: 12915-12920.
24. Ffrench-Constant RH, Rocheleau TA, Steichen JC, Chalmers AE, (1993). A point mutation in a drosophila GABA receptor confers insecticide resistance. Nature 363: 449-451.
25. Gershon MD, Tack J, (2007). The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 132: 397-414.
26. Gunthorpe MJ, Lummis SCR, (1999). Diltiazem causes open channel block of recombinant 5-HT3 receptors. J Physiol 519: 713-722.
27. A channel that abolish block by picrotoxin. Receptors Channels 3: 13-20.
28. 3 receptors in rodents. J Neurochem 75: 240-247.
29. Hapfelmeier G, Haseneder R, Kochs E, Beyerle M, Zieglgansberger W, (2001). Coadministered nitrous oxide enhances the effect of isoflurane on GABAergic transmission by an increase in open-channel block. J Pharmacol Exp Ther 298: 201-208.
30. Hawthorne R, Lynch JW, (2005). A picrotoxin-specific conformational change in the glycine receptor M2-M3 loop. J Biol Chem 280: 35836-35843.
31. Hawthorne R, Cromer BA, Ng HL, Parker MW, Lynch JW, (2006). Molecular determinants of ginkgolide binding in the glycine receptor pore. J Neurochem 98: 395-407.
32. 3A receptor reduces alcohol sensitivity. Brain Res Mol Brain Res 142: 146-150.
33. Hibbs RE, Gouaux E, (2011). Principles of activation and permeation in an anion-selective Cys-loop receptor. Nature 474: 54-60.
34. Hilf RJ, Dutzler R, (2008). X-ray structure of a prokaryotic pentameric ligand-gated ion channel. Nature 452: 375-379.
35. Holbrook JD, Gill CH, Zebda N, Spencer JP, Leyland R, Rance KH, et al. (2009). Characterisation of 5-HT3C, 5-HT3D and 5-HT3E receptor subunits: evolution, distribution and function. J Neurochem 108: 384-396.
36. Höld KM, Sirisoma NS, Ikeda T, Narahashi T, Casida JE, (2000). α-Thujone (the active component of absinthe): γ-aminobutyric acid type A receptor modulation and metabolic detoxification. Proc Natl Acad Sci U S A 97: 3826-3831.
37. 3 receptor by full and partial agonists. Br J Pharmacol 117: 839-846.
38. 3A receptor subunits. Mol Pharmacol 55: 1037-1043.
39. 3A receptor is a molecular determinant of allosteric modulation by 5-hydroxyindole. Neuropharmacology 54: 1153-1165.
40. Jensen AA, Davies PA, Brauner-Osborne H, Krzywkowski K, (2008). 3B but which 3B? And that's just one of the questions: the heterogeneity of human 5-HT(3) receptors. Trends Pharmacol Sci 29: 437-444.
41. Jensen AA, Bergmann ML, Sander T, Balle T, (2010). Ginkgolide X is a potent antagonist of anionic Cys-loop receptors with a unique selectivity profile at glycine receptors. J Biol Chem 285: 10141-10153.
42. 3 receptors. Nature 424: 321-324.
43. 3 receptors in N1E-115 neuroblastoma cells. Br J Pharmacol 112: 541-546.
44. 2+ permeability and conduction in the human 5-hydroxytryptamine type 3A receptor. J Biol Chem 283: 19301-19313.
45. 3AB receptor. Biophys J 98: 1494-1502.
46. 3 receptor-mediated ion current in neuroblastoma cells and isolated adult mammalian neurons. Mol Pharmacol 40: 263-270.
47. 3) receptors. Br J Pharmacol 133: 144P.
48. 3 receptor antagonists: current uses and future directions. Pharmacol Ther 130: 338-347.
49. 3 receptor partial agonist modulation, a novel approach to the treatment of diarrhea predominant irritable bowel syndrome (IBS-D). Gastroenterology 140: S616-S616.
50. 3 receptor, a serotonin-gated ion channel. Science 254: 432-437.
51. 3 receptor: heterogeneity in distribution and function among species. Mol Pharmacol 48: 407-416.
52. 4 ligands: an update of medicinal chemistry research in the last few years. Curr Med Chem 17: 334-362.
53. Morelli E, Gemma S, Budriesi R, Campiani G, Novellino E, Fattorusso C, et al. (2009). Specific targeting of peripheral serotonin 5-HT3 receptors. Synthesis, biological investigation, and structure-activity relationships. J Med Chem 52: 3548-3562.
54. 3 receptors. Eur J Med Chem 45: 4746-4760.
55. Nakamura Y, Ishida Y, Yamada T, Kondo M, Shimada S, (2013). Subunit-dependent inhibition and potentiation of 5-HT3 receptor by the anticancer drug, topotecan. J Neurochem 125: 7-15.
56. 3AB receptor responses. Biochem Biophys Res Commun 415: 416-420.
57. 3 receptors: potential of individual isoforms for personalised therapy. Curr Opin Pharmacol 11: 81-86.
58. Niesler B, Walstab J, Combrink S, Moller D, Kapeller J, Rietdorf J, et al. (2007). Characterization of the novel human serotonin receptor subunits 5-HT3C,5-HT3D, and 5-HT3E. Mol Pharmacol 72: 8-17.
59. Nury H, Van Renterghem C, Weng Y, Tran A, Baaden M, Dufresne V, et al. (2011). X-ray structures of general anaesthetics bound to a pentameric ligand-gated ion channel. Nature 469: 428-431.
60. 3 receptor using a molecular ruler. Biophys J 98: 1847-1855.
61. Palma E, Mileo AM, Eusebi F, Miledi R, (1996). Threonine-for-leucine mutation within domain M2 of the neuronal α7 nicotinic receptor converts 5-hydroxytryptamine from antagonist to agonist. Proc Natl Acad Sci U S A 93: 11231-11235.
62. Peters JA, Cooper MA, Carland JE, Livesey MR, Hales TG, Lambert JJ, (2010). Novel structural determinants of single channel conductance and ion selectivity in 5-hydroxytryptamine type 3 and nicotinic acetylcholine receptors. J Physiol 588: 587-596.
63. Rusch D, Braun HA, Wulf H, Schuster A, Raines DE, (2007). Inhibition of human 5-HT(3A) and 5-HT(3AB) receptors by etomidate, propofol and pentobarbital. Eur J Pharmacol 573: 60-64.
64. Solt K, Stevens RJ, Davies PA, Raines DE, (2005). General anesthetic-induced channel gating enhancement of 5-hydroxytryptamine type 3 receptors depends on receptor subunit composition. J Pharmacol Exp Ther 315: 771-776.
65. Srinivasan R, Richards CI, Dilworth C, Moss FJ, Dougherty DA, Lester HA, (2012). Forster resonance energy transfer (FRET) correlates of altered subunit stoichiometry in Cys-loop receptors, exemplified by nicotinic α4β2. Int J Mol Sci 13: 10022-10040.
66. Stevens R, Rusch D, Solt K, Raines DE, Davies PA, (2005). Modulation of human 5-hydroxytryptamine type 3AB receptors by volatile anesthetics and n-alcohols. J Pharmacol Exp Ther 314: 338-345.
67. C receptors. Br J Pharmacol 153: 1686-1696.
68. 3 receptor as a therapeutic target. Expert Opin Ther Targ 11: 527-540.
69. 3 receptors. Br J Pharmacol 151: 666-677.
70. Thompson AJ, Lester HA, Lummis SC, (2010a). The structural basis of function in Cys-loop receptors. Q Rev Biophys 43: 449-499.
71. Thompson AJ, Verheij MH, Leurs R, De Esch IJ, Lummis SC, (2010b). An efficient and information-rich biochemical method design for fragment library screening on ion channels. Biotechniques 49: 822-829.
72. 3 receptor. Mol Pharmacol 80: 183-190.
73. 3 receptor at a location that overlaps the picrotoxin binding site. Neuropharmacology 60: 488-495.
74. 3AB receptors. J Physiol 589: 4243-4257.
75. Thompson AJ, McGonigle I, Duke R, Johnston GA, Lummis SC, (2012a). A single amino acid determines the toxicity of Ginkgo biloba extracts. FASEB J 26: 1884-1891.
76. 3AB receptors. J Pharmacol Exp Ther 341: 350-359.
77. 3 receptors: inhibition and potentiation of Cys-loop receptor signalling through a conserved transmembrane intersubunits site. J Biol Chem 287: 25241-25254.
78. 3 receptor ligands. J Med Chem 55: 8603-8614.
79. 3 receptors: role in disease and target of drugs. Pharmacol Ther 128: 146-169.
80. 3 receptors. Neuropharmacology 43: 367-373.
81. 3 receptor. Mol Pharmacol 68: 365-371.
82. 3A receptors confer partial agonist and antagonist properties to benzylidene analogs of anabaseine. J Pharmacol Exp Ther 317: 1276-1284.
83. Zhang R, Wen X, Militante J, Hester B, Rhubottom HE, Sun H, et al. (2007). The role of loop F residues in determining differential d-tubocurarine potencies in mouse and human 5-hydroxytryptamine 3A receptors. Biochemistry 46: 1194-1204.
84. Zhorov BS, Bregestovski PD, (2000). Chloride channels of glycine and GABA receptors with blockers: Monte Carlo minimization and structure-activity relationships. Biophys J 78: 1786-1803.